tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Aug 25;10(9):1386.
doi: 10.3390/vaccines10091386.
The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany
Michele A Kohli[SUP] 1 [/SUP], Michael Maschio[SUP] 1 [/SUP], Shannon Cartier[SUP] 1 [/SUP], Joaquin Mould-Quevedo[SUP] 2 [/SUP], Frank-Ulrich Fricke[SUP] 3 [/SUP]
Affiliations
Abstract
Enhanced quadrivalent influenza vaccines that include an adjuvant (aQIV) or a high dose of antigen (QIV-HD), which stimulate a stronger immune response in older adults than the standard vaccine (QIVe), are now approved. The objective of this research is to compare available vaccines and determine the cost-effectiveness of immunizing persons aged 65 years and above with aQIV compared to QIVe and QIV-HD in Germany. A compartmental transmission model calibrated to outpatient visits for influenza in Germany was used to predict the number of medically attended infections using the three vaccines. The rates of hospitalizations, deaths, and other economic consequences were estimated with a decision tree using German data where available. Based on meta-analysis, the rVE of -2.5% to 8.9% for aQIV versus QIV-HD, the vaccines are similar clinically, but aQIV is cost saving compared to QIV-HD (unit cost of EUR 40.55). All results were most sensitive to changes in vaccine effectiveness. aQIV may be cost-effective compared to QIVe depending on the willingness to pay for additional benefits in Germany. As aQIV and QIV-HD are similar in terms of effectiveness, aQIV is cost saving compared to QIV-HD at current unit prices.
Keywords: MF59-adjuvanted quadrivalent influenza vaccine; MF59-adjuvanted trivalent influenza vaccine; TIV-HD; aQIV; aTIV; cost saving; cost-effectiveness; high-dose trivalent influenza vaccine; rVE; relative vaccine efficacy.
. 2022 Aug 25;10(9):1386.
doi: 10.3390/vaccines10091386.
The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany
Michele A Kohli[SUP] 1 [/SUP], Michael Maschio[SUP] 1 [/SUP], Shannon Cartier[SUP] 1 [/SUP], Joaquin Mould-Quevedo[SUP] 2 [/SUP], Frank-Ulrich Fricke[SUP] 3 [/SUP]
Affiliations
- PMID: 36146464
- DOI: 10.3390/vaccines10091386
Abstract
Enhanced quadrivalent influenza vaccines that include an adjuvant (aQIV) or a high dose of antigen (QIV-HD), which stimulate a stronger immune response in older adults than the standard vaccine (QIVe), are now approved. The objective of this research is to compare available vaccines and determine the cost-effectiveness of immunizing persons aged 65 years and above with aQIV compared to QIVe and QIV-HD in Germany. A compartmental transmission model calibrated to outpatient visits for influenza in Germany was used to predict the number of medically attended infections using the three vaccines. The rates of hospitalizations, deaths, and other economic consequences were estimated with a decision tree using German data where available. Based on meta-analysis, the rVE of -2.5% to 8.9% for aQIV versus QIV-HD, the vaccines are similar clinically, but aQIV is cost saving compared to QIV-HD (unit cost of EUR 40.55). All results were most sensitive to changes in vaccine effectiveness. aQIV may be cost-effective compared to QIVe depending on the willingness to pay for additional benefits in Germany. As aQIV and QIV-HD are similar in terms of effectiveness, aQIV is cost saving compared to QIV-HD at current unit prices.
Keywords: MF59-adjuvanted quadrivalent influenza vaccine; MF59-adjuvanted trivalent influenza vaccine; TIV-HD; aQIV; aTIV; cost saving; cost-effectiveness; high-dose trivalent influenza vaccine; rVE; relative vaccine efficacy.